Honeywell

Abstract Preview

Here is the abstract you requested from the medical_2018 technical program page. This is the original abstract submitted by the author. Any changes to the technical content of the final manuscript published by IMAPS or the presentation that is given during the event is done by the author, not IMAPS.

Molecular Cloning Involving the AAV CXCL12 Gene
Keywords: Cloning , Nanotechnology , Drug Delivery
The American Cancer Society reports that this year there will be an estimated 600, 920 deaths due to cancer in the United States. Current cancer research includes the use of biomarkers on the surface of cancer cells to distinguish the cancerous cells from normal body cells. Molecular cloning can enhance these biomarkers. Over the past thirty years, molecular cloning has progressed immensely. From digestion to plasmid insertion, the possibilities are endless. The AAV (Adeno Associated Virus) CXCL 12(C-X-C Motif Chemokine Ligand 12) is a Protein Coding gene that shows great promise with cloning and plasmid insertion. Our project aims to use this gene to bind tightly to biomarkers on the surface of cancer cells. However before this optimal binding can occur, it is essential to know more about the AAV CXCL 12 Gene itself. For this reason, our project includes multiple gel electrophoresis assays, plasmid insertion/digestion assays, and PCR purification. From the results of these assays, the efficacy of AAV CXCL 12 to bind to cancer biomarkers will become clear. In particular, the cloning assay for the AAV CXCL 12 gene holds great potential, as it is possible to clone extraneous DNA into a different host. If extraneous DNA can be cloned into a different host, then there is the possibility of that DNA binding to a biomarker on a cancer cell. Furthermore, the AAV CXCL 12 gene is known to have sustained drug delivery. If a novel nanotechnology could be created where the gene could be inserted inside and then sustainably delivered, cancer treatment could be revolutionized. The idea of a drug delivery mechanism that includes biomarkers is something that has never been done before. Cancer research with nanotechnology today focuses on the targeting of the CXCL 12 genes receptor the CXCR 4 gene. The chemokine axis between them is known to play a large role in tumor metastasis. Additionally, recent research shows that the CXCL 12 gene can become resistant to Human Immunodeficiency Virus 1. The gene also shows potential with remylination of white matter in damaged brain cells. Because of this, cloning focusing on retaining the biomarking efficacy of the CXCL 12 gene in host DNA will prove to be successful, as the gene has many other values aside from biomarking. To accurately test the CXCL 12 gene, a control gel electrophoresis assay will be conducted. This assay will then be used in comparison with the gene is digested into new plasmid vectors. If the gene can be successfully digested into new plasmid vectors and the biomarking efficacy retained, then the gene will hopefully be translated into new host DNA and whether or not the biomarking is expressed will be noted. It will also be important to note if sustained delivery, resistance to Human Immunodeficiency Virus 1, and remylination will occur in the plasmid vector as well as the new host DNA. Much of cancer research also aims to produce antibodies to bind to the CXCL 12s gene receptor the CXCR 4 gene. With these antibodies, the goal is that tumor metastasis that occurs with the particular chemokine axis will be decreased or even stop. Thus, when if the CXCL 12 gene is successfully cloned, the effect of antibodies on its receptor will reveal much about the gene itself. In conclusion, the CXCL 12 gene has significant potential. A known biomarker, resistant to HIV, and an avid neurological benefiter; the gene should be researched on. A gel electrophoresis assay control first testing the gene, then digesting the gene into a plasmid vector, and ultimately attempting to insert the gene into new DNA will divulge significant information about the gene.
Kripa Raj Ahuja ,
UNC Chapel Hill
Chapel Hill, NC
United States


CORPORATE PREMIER MEMBERS
  • Amkor
  • ASE
  • Canon
  • EMD Performance Materials
  • Honeywell
  • Indium
  • Kester
  • Kyocera America
  • Master Bond
  • Micro Systems Technologies
  • MRSI
  • NGK NTK
  • Palomar
  • Plexus
  • Promex
  • Qualcomm
  • Quik-Pak
  • Raytheon
  • Specialty Coating Systems